10 янв. 2023 г. · AbbVie's reconciliation tables. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding ...

3 янв. 2023 г. · 3, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.

AbbVie. Presenting: Tuesday, January 10, 2023 at 03:00 PM PST. Room: Grand Ballroom. Speakers: Richard Gonzalez Chairman of the Board, Chief Executive Officer, ...

The document is a presentation from Rick Gonzalez, Chairman and CEO of AbbVie, at the J.P. Morgan Healthcare Conference on January 10, 2023.

10/01/2023 - AbbVie Inc.: J.P. Morgan Healthcare Conference Presentation 815.6 KB ; Best-in-Class. Large, established. Positioned for ; medicines position.

10 янв. 2024 г. · At the J.P. Morgan conference, AbbVie president Robert Michael said the company must effectively integrate ImmunoGen and Cerevel, ...

10 янв. 2023 г. · AbbVie Inc. (NYSE:ABBV) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 6:00 PM ET. Company Participants.

News AbbVie Inc. Transcript : AbbVie Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 03.

15 сент. 2024 г. · In 2023, Humira generated $14 billion in revenues, or 27% of AbbVie's total top line for the year. While Humira is AbbVie's headliner, the ...

12 апр. 2023 г. · Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025. Estimates have ...